Latest Breaking News On - Indaptus therapeutics - Page 1 : vimarsana.com

Indaptus Therapeutics (NASDAQ:INDP) Shares Down 10.1%

Indaptus Therapeutics, Inc. (NASDAQ:INDP – Get Free Report) was down 10.1% during trading on Thursday . The stock traded as low as $2.40 and last traded at $2.48. Approximately 40,955 shares changed hands during mid-day trading, a decline of 30% from the average daily volume of 58,922 shares. The stock had previously closed at $2.76. […]

Securities-exchange-commission
Indaptus-therapeutics-inc
Nasdaq
Indaptus-therapeutics-company-profile
Virtu-financial
Indaptus-therapeutics
Get-free-report
Free-report
Indaptus-therapeutics-daily

Indaptus Therapeutics : Material Event - Form 8-K

Item 8.01. Other Events. On May 22, 2024, Indaptus Therapeutics, Inc. announced the successful advancement of its Phase I trial investigating Decoy20. .

United-states
American
Indaptus-therapeutics-inc
Safety-review-committee-of-the-company
American-society-of-clinical-oncology
Indaptus-therapeutics
Safety-review-committee
American-society
Clinical-oncology

Indaptus Therapeutics Announces Completion of First Patient to Receive Multiple Doses of Decoy20

Indaptus Therapeutics, Inc. announced the successful advancement of its Phase 1 trial for Decoy20, an investigational novel package of broad immune agonists for cancer immunotherapy that has.

United-states
American
American-society-of-clinical-oncology
Safety-review-committee
Indaptus-therapeutics-inc
Indaptus-therapeutics
American-society
Clinical-oncology

INDP Stock Earnings: Indaptus Therapeutics Misses EPS for Q1 2024

INDP Stock Earnings: Indaptus Therapeutics Misses EPS for Q1 2024
biztoc.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from biztoc.com Daily Mail and Mail on Sunday newspapers.

Indaptus-therapeutics
Place-earnings

Indaptus Therapeutics' (INDP) "Buy" Rating Reiterated at HC Wainwright

HC Wainwright restated their buy rating on shares of Indaptus Therapeutics (NASDAQ:INDP – Free Report) in a research note released on Monday morning, Benzinga reports. HC Wainwright currently has a $12.00 price objective on the stock. HC Wainwright also issued estimates for Indaptus Therapeutics’ Q1 2024 earnings at ($0.57) EPS, Q2 2024 earnings at ($0.60) […]

Indaptus-therapeutics-inc
Northern-trust-corp
Citadel-advisors
Renaissance-technologies
Vanguard-group-inc
Indaptus-therapeutics
Free-report
Therapeutics-trading-down
Get-free-report
Trust-corp
Street-corp